ARGENX SE (ARGX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $868.80, ARGENX SE (ARGX) is priced for today's economics sustained for ~7.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-10 · Exported: 2026-08-11 · Source: https://boothcheck.com/report/ARGX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.5% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.1 years.

How unusual the bet is: elevated

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.3%); the inversion above states its own rate.

Per-Model Detail (n=16)

Solvency

Bullet Takeaways

• One molecule carries everything: the FY2025 20-F records "net sales of $4.2 billion from global product net sales of VYVGART for the year ended December 31, 2025", and the same filing cautions that profitability cannot be assured on the current indications alone.
• Growth is coming from adding diseases rather than adding drugs, and the newest addition landed on May 8, 2026 when the FDA expanded the label to cover every adult serotype of generalized myasthenia gravis.
• The balance sheet carries no funded borrowings at all, which removes the usual failure mode for a company priced this far ahead of its earnings and leaves execution as the only thing that can go wrong.

Bull Case

Seventeen consecutive quarters of growth is the number that does not fit the usual pattern. Drug launches follow a shape: a steep ramp, a plateau as the diagnosed-and-treated pool fills, then a grind. VYVGART has not done that. The FY2025 20-F records the drug "surpassing $1 billion in product net sales in a single quarter for the first time in the third quarter of 2025", and the first quarter of 2026 brought 1.3 billion dollars of global product net sales, up 63% on the year, marking the seventeenth straight quarter of growth. Four years into a launch, acceleration rather than deceleration is the observation worth explaining.

The explanation is that this is not one launch. It is a sequence of them running through the same molecule. Efgartigimod blocks a single mechanism, the neonatal Fc receptor that recycles the antibodies causing several autoimmune diseases, so every disease driven by that mechanism is a potential label rather than a potential research program. The 20-F reports commercial revenue from generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia in Japan, with a table of approvals spanning intravenous, subcutaneous and prefilled-syringe presentations across jurisdictions. Each addition reuses the manufacturing, the safety database and the specialist sales force already paid for. That is why the operating margin runs at 25.4% while revenue compounds, which is a combination that ordinarily does not coexist.

The most recent addition shows the machine working. On May 8, 2026 the FDA expanded VYVGART and VYVGART Hytrulo to all adult patients with generalized myasthenia gravis, covering anti-AChR, anti-MuSK, anti-LRP4 and triple-seronegative patients, after a trial that met its primary endpoint on the standard daily-living score at week four. Seronegative patients had no approved targeted option. The addressable population in the company's oldest indication just widened without a single new molecule entering the clinic.

Capital deployment reflects the same logic. There is no funded debt, and the company closed the first quarter of 2026 with 4.9 billion dollars of cash, cash equivalents and current financial assets. Share count has grown about 4.7% a year over the four years to the end of 2025, which for a company that funded a global commercial build without borrowing is a modest price. Management's own incentives point where the money goes: the 20-F discloses that for the 2026 short-term incentive plan, the chief executive's targets are weighted 50% to delivering the 2026 revenue plan and 25% to pipeline acceleration, with specific readouts named. Paying the leadership to deliver both the current product and the next three is not sophisticated. It is just aligned.

Returns confirm the model rather than merely describing it. Return on invested capital runs at 21.5% against a cost of capital in the mid-single digits, and return on equity at 17.6% on a book value of 119.47 dollars a share. A business earning that spread while growing at this rate does not need external capital to do it, which is the definition of a self-funding compounder.

Bear Case

The variable with the most leverage on this thesis is not competition or science. It is who sets the price. The 20-F describes European systems in which member states either fix a specific price for a product or impose direct and indirect controls on the profitability of the company placing it on the market, with others allowing free pricing while monitoring volumes and issuing guidance to physicians to limit prescriptions. It states plainly that products launched in the EU do not follow U.S. price structures. It also notes that further approvals and launches are planned "following pricing and reimbursement negotiations". Every incremental country is therefore a negotiation, and each one is conducted by a counterparty whose stated objective is to pay less.

In the United States the pressure runs through a different channel and arrives at the same place. The filing warns that payors may treat products as substitutable and reimburse only the less expensive one, that the pricing of existing drugs can cap what a new product charges even where it shows better efficacy or convenience, and that state legislatures are increasingly enacting laws designed to control pharmaceutical prices. It expects pricing pressure to continue globally. A price this far above what the underlying earnings support is implicitly assuming that per-patient revenue holds while patient counts grow. Regulators and payors have the opposite objective and considerably more staying power.

The exclusivity clock is the third external variable, and the filing raises the possibility that it runs faster than expected. The 20-F warns that the company's products could serve as reference products for competing versions, "potentially creating the opportunity for competition by biosimilar products sooner than anticipated", and notes the same risk in the EU where exclusivity could be shortened by legislative action. For a single-molecule company, biosimilar entry is not a segment event. The 20-F says as much in its own words: notwithstanding the 4.2 billion dollars of VYVGART net sales in 2025 which support current profitability, the company "cannot provide assurances that we will be profitable or able to sustain net profitability in the future based on these indications alone".

Set that against what the price requires. The market is paying about 50.7 times the company's annual operating profit, and the arithmetic behind that multiple works only if operating growth runs at roughly its self-funding ceiling for about 8.4 years. The company has recently delivered that rate, so the demand is not about the pace. It is about persistence, and persistence is where the record thins out: among comparable fast-growers, only about 23% held that pace for a stretch of that length. If growth fades earlier, the multiple does not settle at a premium to the sector. It settles wherever a profitable specialty pharmaceutical with a maturing franchise trades, and the distance between those two outcomes is most of the current quote.

Competition is the accelerant rather than the cause. The 20-F describes intense competition in autoimmune disease from monoclonal antibodies, other biologics and small molecules marketed or in development by many companies, including large pharmaceutical firms with deeper commercial reach. Rivals in the same mechanism do not need to be better to hurt. They only need to give a payor a second option to negotiate against.

Valuation

Start with the shape of the demand rather than its size. The market is paying about 50.7 times the company's annual operating profit, and inverting that multiple does not produce a margin target. It produces a stopwatch. What the price requires is that operating growth run at roughly the ceiling the business can fund from its own cash for about 8.4 years. The margin is not the constraint here; the company already earns more than the price needs it to. Time is the constraint.

That distinction matters because it changes which evidence counts. Against the company's own record the required pace is unremarkable, and it has recently delivered it. Against the broader record it is demanding: among comparable fast-growers, roughly 23% sustained that pace across a span of that length. One caveat belongs with the figure. It is a single solve under fixed assumptions, and it is sensitive to the discount rate, with each percentage point of cost of capital moving the implied horizon by roughly 2.1 years. Treat it as a boundary on the argument rather than a measurement of it.

Every family of method lands below the current quote, and none of them reaches it. Asset-value approaches, working from 119.47 dollars of book value per share and a 17.6% return on equity, come out at a fraction of the price. Earnings-power approaches, which capitalize today's profit with no growth credited, land lowest of all. Peer-multiple approaches land above those but still short. Even the forward-growth approaches, which do credit the recent trajectory, do not get there. There is no valuation family under this price supporting it; the entire gap is a claim about duration that no standard frame is built to encode. That is the honest description of what is being underwritten.

The peer cohort clarifies the profitability question without settling the duration one. NBIX earns a 25.4% operating margin on 3.10 billion dollars of revenue while growing 28.6%, a profile close to this one at slightly smaller scale. ALNY earns 13.5% on 3.71 billion while growing 65.2%, trading margin for pace. IDXX earns 31.6% on 4.45 billion while growing 13.1%, the mature end of the same trade-off. Argenx sits at 4.25 billion of revenue with a 25.4% operating margin, meaning it is currently getting both the growth and the margin. The cohort shows how rarely those travel together and offers no example of them doing so indefinitely.

On the balance sheet there is genuinely little to argue about. The company carries no funded borrowings, is not burning cash, and closed the first quarter of 2026 with 4.9 billion dollars of cash, cash equivalents and current financial assets. The share count has grown about 4.7% a year over the four years to the end of 2025, a mild dilution against a commercial build financed without debt. What that balance sheet does is remove insolvency from the list of things that can go wrong. What it does not do is shorten the horizon the price is counting on.

Catalysts

The first quarter of 2026 was the seventeenth consecutive quarter of growth for the franchise. Global product net sales reached 1.3 billion dollars against 790 million a year earlier, total operating income rose to 1.3 billion from 807 million, and operating profit more than doubled to 394 million from 139 million, with net profit of 366 million against 169 million. Operating profit growing faster than sales is the specific detail: the commercial infrastructure is already built, so incremental revenue is arriving at a better rate than the average dollar already booked.

The regulatory event of the year has already landed. On May 8, 2026 the FDA expanded VYVGART and VYVGART Hytrulo to all adult patients with generalized myasthenia gravis, including anti-AChR-positive, anti-MuSK-positive, anti-LRP4-positive and triple-seronegative patients, after the registrational study met its primary endpoint on the daily-living score at week four. Seronegative patients previously had no targeted approved option, so this widens the oldest indication rather than opening a new one.

Two readouts sit in front of the market for the rest of the year. Myositis data from the ALKIVIA program is expected in the third quarter of 2026, and the registrational EMPASSION readout in multifocal motor neuropathy is planned for the fourth. Both are new diseases for the same molecule, which is what makes them consequential: a positive result extends the franchise without extending the research risk, and a negative one narrows the runway the price is leaning on. The 20-F itself ties management's 2026 incentive plan to delivering those readouts alongside the revenue plan, which is a fair guide to what the company considers this year's scoreboard.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• IDXX (IDEXX LABORATORIES INC /DE)
• FY2025 10-K: …operator of corporate hospital chains that also sells veterinary point-of-care diagnostic instruments. Consolidation among our competitors and our customers may intensify the competition we face. While we believe that our offerings are competitively differentiated due to our innovative products and services that…
• FY2025 10-K: …our competition, refer to "Part I, Item 1A. Risk Factors." Competitive factors in our different business areas are detailed below: • Companion animal diagnostic offerings . We compete primarily on the basis of ease of use and speed of our products, diagnostic accuracy, product quality, breadth of our product line and…
• ALNY (ALNYLAM PHARMACEUTICALS, INC.)
• FY2025 10-K: …• patent position. Our competitors may develop or commercialize products with significant advantages over any products we or our collaborators develop based on any of the factors listed above or on other factors. In addition, our competitors may enter into collaborations with or receive funding from larger…
• FY2025 10-K: …the potential to become a leading therapy for ATTR amyloidosis and to significantly improve our gross margins on product sales and our non-GAAP operating income margin. Results of Operations The following table summarizes the results of our operations: Years Ended December 31, 2025 vs 2024 2024 vs 2023 (In thousands,…
• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …immunological disorders. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief…
• FY2025 10-K: …conflicts. General business and economic conditions that could affect our business, financial condition or results of operations include fluctuations in economic growth, inflation and interest rates, debt and equity capital markets, liquidity of the global financial markets, the availability and cost of credit,…
• NTRA (NATERA, INC.)
• FY2025 10-K: ​ 1,267 Gross margin ​ $ 1,493,180 ​ $ 1,023,158 ​ $ 492,740 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross margin percentage ​ ​ 64.7 % ​ ​ 60.3 % ​ ​ 45.5 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 128 Table of Contents ​ ​ 17. Subsequent Events Subsequent to December 31, 2025, the Company entered into a new lease arrangement for additional laboratory space…
• FY2025 10-K: …disclosure of incremental segment information on an interim and annual basis that are regularly provided to the chief operating decision maker (the "CODM") and included within each reported measure of segment profit or loss. The Company has adopted this ASU as of December 31, 2024. The Company currently operates as a…
• MRNA (Moderna, Inc.)
• FY2025 10-K: …market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as a wide range of pricing, discounting, structuring and commissions, certain customer incentive programs and other business arrangements, are subject to extensive laws designed…
• FY2025 10-K: …statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ…
• RDNT (RadNet, Inc.)
• FY2025 10-K: …high and lesions can be difficult to find, such as in screening mammography. AI can also improve business processes to better effectively serve customers and improve reimbursement and collections accuracy. Competition Our competitors include independent imaging operators and smaller regional operators, as well as…
• FY2025 10-K: …of service procedures that we provide, a decline in reimbursement rates will reduce our net revenues and results of operations. If we fail to manage the complex and lengthy reimbursement process, our revenue, financial condition and results of operations could suffer. Because our business depends upon reimbursement…
• ALKS (Alkermes plc.)
• FY2025 10-K: …which could materially adversely effect our business, financial condition, cash flows and results of operations. 44 Our success largely depends upon our ability to attract, recognize and retain key personnel. Our ability to compete and succeed in the highly competitive biopharmaceutical industry and in the disease…
• FY2025 10-K: …condition, cash flows and results of operations; • our success largely depends upon our ability to attract, recognize and retain key personnel, and the loss of key personnel may materially and adversely impact our business; • patent and other IP protection for our products is key to our business and our competitive…
• HALO (HALOZYME THERAPEUTICS, INC.)
• FY2025 10-K: …pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of…
• FY2025 10-K: …and results of operations. To help patients afford certain of our products, we offer discount, rebate, and co-pay coupon programs. CMS recently has issued a regulation imposing additional obligations on manufacturers in order to continue excluding such programs from government pricing calculations to avoid payment of…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.